All companies
Visit website
Actipulse Neuroscience
OperatingActipulse Neuroscience, Inc.
Healthcare · Founded 2019
Minority-founded
Bringing neuromodulation treatment for depression, from the hospital to the home
Valuation cap ⓘ
$10.0M
As of Nov 2021 · from Actipulse Neuroscience Crowd SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$201,600
Across 1 round since 2021
Latest share price
$1.00
Actipulse Neuroscience Crowd SAFE 1 offering price
Financials
FY2019–FY2022 · from SEC filings · hover any figure for its source$583K
$79K
2019
$248K
$26K
2020
$3K
−$25K
2021
$174K
$9K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$583,433
$248,406
$2,609
$173,963
Cost of goods sold
$172,299
$6,267
$138
$1,928
Gross margin
70%
97%
95%
99%
Net income
$79,323
$26,070
-$24,691
$9,308
Taxes paid
$34,723
$33,720
$0
$0
Balance sheet
Cash
$22,189
$43,612
$233,595
$828,839
Accounts receivable
$187,973
$182,624
$182,624
$182,624
Total assets
$329,668
$438,383
$685,366
$1,654,564
Short-term debt
$184,420
$94,111
$96,654
$146,013
Long-term debt
$0
$172,654
$172,654
$172,654
Total liabilities
$184,420
$266,765
$269,308
$318,667
Other
Headcount
—
0
0
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.0M
Valuation cap
Actipulse Neuroscience Crowd SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $201.6K / $1.1MInvestors 498Valuation cap $10M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 2 of 5 annual reports (FY2021–FY2025)
498 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001860502Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.